German DRG (diagnosis related groups) amendments will hinder innovation, claims opposition
This article was originally published in Clinica
Executive Summary
The German government's second amendment to the diagnosis related groups (DRG) law is endangering medical innovation in university hospitals. This was the view voiced by the opposition Christian Democratic and Socialist Union (CDU/CSU) parties following the second and third readings of the draft law in the Lower House (Bundestag) of parliament.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.